Clinical Trials Browser

Phase 3 × INDUSTRY × apatinib × Clear all

NCT06346392 2026-05-27

AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2

Phase 3 Active not recruiting

Gastrointestinal

Stomach Neoplasms

NCT04342910 2026-01-20

Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC

Phase 3 Recruiting

Gastrointestinal

Stomach Neoplasms

NCT04639180 2025-12-30

A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation

Phase 3 Active not recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT03813784 2025-09-16

A Clinical Study To Evaluate Camrelizumab (SHR-1210) Plus Capecitabine and Oxaliplatin Followed by Sequential Treatment With Camrelizumab Plus Apatinib Mesylate in Advanced or Metastatic Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJ) Without Prior Systemic Therapy

Phase 3 Completed

Gastrointestinal

Stomach Neoplasms

NCT03764293 2024-02-06

A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCC

Phase 3 Completed

543 enrolled 13 charts

Neoplasm Metastasis

NCT02329860 2024-01-22

Study of Apatinib After Systemic Therapy in Patients With Hepatocellular Carcinoma(AHELP)

Phase 3 Completed

400 enrolled 13 charts

Gastrointestinal

Carcinoma, Hepatocellular

NCT04714190 2023-12-21

A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression

Phase 3 Unknown

Gastrointestinal

Stomach Neoplasms

NCT04335006 2023-05-06

A Phase 3 Study Comparing Carelizumab Plus Nab-paclitaxel and Apatinib, Carelizumab Plus Nab-paclitaxel, and Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer.

Phase 3 Terminated

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03042611 2022-07-08

ANGEL

Phase 3 Completed

460 enrolled 16 charts

Gastrointestinal

Neoplasm Metastasis, Neoplasms, Stomach Neoplasms

NCT04229615 2022-04-25

A Study of Fluzoparib±Apatinib Versus Placebo Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on First-Line Platinum-Based Chemotherapy

Phase 3 Unknown

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04296370 2020-08-10

A Study of Fluzoparib±Apatinib Versus Chemotherapy Treatment of Physician's Choice in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation

Phase 3 Unknown

Treatment in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation

NCT04203485 2020-05-08

Camrelizumab Combined With Apatinib Mesylate or Camrelizumab Alone for First-line Treatment in Subjects With Programmed Death Ligand 1 (PD-L1) Positive Relapsed or Advanced Non-small Cell Lung Cancer (NSCLC)

Phase 3 Unknown

PD-L1 Positive Non-small Cell Lung Cancer

NCT04000295 2019-10-08

Apatinib and Etoposide Capsule Versus Weekly Paclitaxel in Patients With Platinum Resistant Ovarian Cancer

Phase 3 Unknown

Ovarian Neoplasms

NCT02332512 2017-02-24

ANSWER

Phase 3 Unknown

Carcinoma, Non-Small-Cell Lung

NCT01512745 2016-10-17

Phase III Study of Apatinib Tablets in the Treatment of Advanced or Metastatic Gastric Cancer

Phase 3 Completed

267 enrolled 11 charts

Gastrointestinal

Stomach Neoplasms